Insider Transactions in Q2 2021 at Eloxx Pharmaceuticals, Inc. (ELOX)
Insider Transaction List (Q2 2021)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 25
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,835
-5.49%
|
$1,835
$1.39 P/Share
|
May 25
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+15.75%
|
-
|
May 13
2021
|
Tomer Kariv Director |
BUY
Open market or private purchase
|
Indirect |
5,925,925
+43.52%
|
$5,925,925
$1.35 P/Share
|
May 13
2021
|
Ran Nussbaum Director |
BUY
Open market or private purchase
|
Indirect |
5,925,925
+43.52%
|
$5,925,925
$1.35 P/Share
|
May 13
2021
|
Pontifax Management 4 G.P. (2015) Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,925,925
+43.52%
|
$5,925,925
$1.35 P/Share
|
May 13
2021
|
Rajesh B Parekh Director |
BUY
Open market or private purchase
|
Indirect |
2,466,666
+33.04%
|
$2,466,666
$1.35 P/Share
|
Apr 30
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
459
-1.66%
|
$918
$2.18 P/Share
|
Apr 30
2021
|
Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
1,562
+5.35%
|
-
|
Apr 01
2021
|
Rajesh B Parekh Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,532,270
+50.0%
|
-
|